Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959750 | 0.82 | DHODH (0.51) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL2965597 | 0.80 | DHODH (0.49) | IKBKBMAOADHODHACMSDKDR | |
| SCHEMBL2961683 | 0.79 | ALDH1A1 (0.51) | IKBKBTTRALBMAOACNR1 | |
| SCHEMBL2963270 | 0.77 | EIF4E (0.42) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL2965645 | 0.77 | KDM4E (0.49) | DHODHKDM4EMAPTGPR35ALDH1A1 | |
| SCHEMBL2957218 | 0.76 | HTR3A (0.67) | PDE4DALDH1A1CYP1A2CYP2C9KCNH2 | |
| SCHEMBL2957215 | 0.76 | HTR3A (0.67) | PDE4DALDH1A1CYP1A2CYP2C9KCNH2 | |
| SCHEMBL2953614 | 0.76 | MAPT (0.50) | IKBKBKDRKDM4EPOLBMAPT | |
| SCHEMBL2961277 | 0.76 | HTR3A (0.53) | KCNH2 | |
| SCHEMBL2963283 | 0.75 | KMT2A (0.40) | TTRALBMAOACNR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781430-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7307094-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1853597-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR Technology, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089100-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | HTR3E, BRS3, HTR3A | IKBKB 983/4885TTR 4860/4885ALB 4154/4885 |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | HTR3E, BRS3, HTR3A | IKBKB 983/4885TTR 4860/4885ALB 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.